Dr. Lakshmi Aggarwal, MD

Dr. Aggarwal practices at Lutheran Hospital of Indiana in Fort Wayne, Indiana.

Dr. Aggarwal's NPI, 1528060431, was assigned on August 10, 2005. Dr. Aggarwal holds Indiana license 01050794A.

Dr. Aggarwal's primary practice is Lutheran Hospital of Indiana, at 7950 W Jefferson Blvd, Fort Wayne, IN 46804 in Allen County. The practice phone is (260) 435-7001.

Dr. Aggarwal's primary practice is Lutheran Hospital of Indiana in Fort Wayne, Indiana. The medical group on file is Fort Wayne Medical Oncology and Hematology. Dmand AI also links Dr. Aggarwal to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Aggarwal practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Aggarwal's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Aggarwal is licensed in Indiana.

CMS data shows 184 Medicare services from Dr. Aggarwal across 3 procedure codes in 2024, for 140 Medicare patients. Medicare paid $19,229 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 140 Medicare patients who saw Dr. Aggarwal in 2024. The largest group is 65 to 74, with 58 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 16% are also on Medicaid. Their average risk score is 2.63, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Aggarwal's median patient age at 64, with 53% women.

In 2022, Dr. Aggarwal wrote 43 Medicare Part D claims. Every claim was for a generic drug. They cover 2 drugs, with $1,293 in total drug cost. In 2021, CMS named 690 claims across 17 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Aggarwal for performance year 2024, reported as part of a group.

Dmand AI links 1 paper to Dr. Aggarwal in 2011. Dr. Aggarwal's most frequent co-authors are Erica Rachel Podolsky, MD, Irfan Saeed, MD and Scott Saehun Um, MD.

Dmand AI links Dr. Aggarwal to 2 clinical trials, 2 of them phase 3 studies. 1 is still active or recruiting. Conditions studied include Breast Neoplasms, Multiple Endocrine Neoplasia Type 1 and Breast Diseases.

CMS Open Payments shows 55 general payments to Dr. Aggarwal from 33 drug and device companies from 2016 to 2024. Food and beverage make up the largest share, 96% of the total. Genentech, Inc. paid the most, $564.